Media.Player

Multipotent Amniotic Fetal Stem Cells: A Novel Source of Human Stem Cells

Technology Benefits

Valuable source of multipotent cells with extensive therapeutic potential. Unhampered source of human stem cells—no political or ethical obstacles.  Can be propagated in an undifferentiated state in culture for long periods of time (about 60 doublings) and are able to differentiate into all three primary germ cells. Cells also appear to be devoid of tumorgenic properties.

Detailed Technology Description

Scientists at UC San Diego have developed methods for isolating, identifying, expanding, and differentiating a novel source of epithelioid multipotent amniotic fetal stem cells with typical hES markers. The isolated stem cells have been characterized and have been shown to express typical hES-cell markers (characterized by expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4, CD105, and SSEA1). The technology provides a method for preparing multipotent stem cells from amniotic fluid and includes harvesting from amniotic fluid; culturing, identifying, and isolating epithelioid stem-cells; and expanding the cells to an undifferentiated state. The number of differentiated pathways and the control of these pathways in culture suggest widespread applications of the new cells.

Supplementary Information

Patent Number: US7569385B2
Application Number: US2004918739A
Inventor: Haas, Martin
Priority Date: 14 Aug 2003
Priority Number: US7569385B2
Application Date: 13 Aug 2004
Publication Date: 4 Aug 2009
IPC Current: C12N000500 | A01N000102 | C12N0005073 | C12N0005074 | C12N000510 | G01N003348 | G01N003350 | G06F001900
US Class: 435325 | 435402 | 435455
Assignee Applicant: The Regents of the University of California
Title: Multipotent amniotic fetal stem cells
Usefulness: Multipotent amniotic fetal stem cells
Summary: The composition and methods are useful for growing stem cell lines that can create differentiated cells, such as specific cell types or tissue types, which are capable of being transplanted into an individual. The cells may be used to treat e.g. cirrhosis of the liver, diabetes, Parkinson's disease, stroke, burns, heart disease, cancer, osteoarthritis and Alzheimer's disease. A large number of other diseases are disclosed in the specification.
Novelty: New composition comprising multipotent or pluripotent stem cells derived from amniotic fluid, useful in cell replacement therapy or for treating diseases such as diabetes, Parkinson's disease, stroke, burns, heart disease or cancer

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

7569385

Others

Intellectual Property Information

See U.S. Letters Patent 7,569,385.

Tech ID/UC Case

19481/2005-041-0

Related Cases

2005-041-0, 2005-042-2

*Abstract

Stem cells have the potential to differentiate into a wide variety of specialized cell types. They can be used for basic research, drug discovery and, ultimately, for the treatment and prevention of disease. However, a major obstacle is that human embryonic stem (hES) cells are derived from the inner cell mass of blastocysts and derivation is encumbered by political and ethical dilemmas. Additionally, human embryonic stem cells have been found to be tumorgenic when injected into immunologically-impaired animals. Furthermore, while human embryonic stem cells potentially differentiate into multiple types of functional cells in vivo, controlled, large-scale differentiation of hES cells into specific cell types in culture has not yet been definitively demonstrated.

*IP Issue Date

Aug 4, 2009

*Principal Investigator

Name: Martin Haas

Department:

Country/Region

USA